PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27463358-3	1991	Six years later, an increased serum M-protein became evident (IgG$LD, 3 gr/dl) associated with 35% plasma cells in the bone marrow, which necessitated melphalan/prednisone therapy.	Melphalan	151-160	myomesin 2	Homo sapiens	36-45	
1232529-3	1975	The group of patients receiving melphalan and prednisone 0.6 mg/kg had significantly improved responses in hemoglobin, lowering of the M-protein concentration, and reduction of azotemia.	Melphalan	32-41	myomesin 2	Homo sapiens	135-144	
3223339-0	1988	M-protein kinetics in multiple myeloma treated with melphalan, ifosfamide, prednisolone, nitrosourea and vincristine in combination.	Melphalan	52-61	myomesin 2	Homo sapiens	0-9	
3177368-2	1988	The M-protein and bone pain disappeared within 6 weeks after therapy with melphalan and prednisone was started.	Melphalan	74-83	myomesin 2	Homo sapiens	4-13	
3367382-1	1988	The average relative dose intensity (DI) of conventional oral melphalan and prednisone therapy received by 93 newly diagnosed multiple myeloma patients was correlated with survival and with percent reduction in M-protein.	Melphalan	62-71	myomesin 2	Homo sapiens	211-220	
27516004-9	2017	Twenty-eight months after melphalan therapy the M-protein reappeared in the serum, and 2 months later SPD reappeared with histopathologically proven skin lesions at predilection sites.	Melphalan	26-35	myomesin 2	Homo sapiens	48-57